Related references
Note: Only part of the references are listed.Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen
Denise A. Yardley et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis
Joyce O'Shaughnessy et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Nab-Paclitaxel/Bevacizumab/Carboplatin Chemotherapy in First-Line Triple Negative Metastatic Breast Cancer
Erika Hamilton et al.
CLINICAL BREAST CANCER (2013)
Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer
Andrew D. Seidman et al.
CLINICAL BREAST CANCER (2013)
Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
Sophie Gourgou-Bourgade et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Phase II Multicenter Trial of Albumin-Bound Paclitaxel and Capecitabine in First-Line Treatment of Patients With Metastatic Breast Cancer
Lee S. Schwartzberg et al.
CLINICAL BREAST CANCER (2012)
Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival
William J. Gradishar et al.
CLINICAL BREAST CANCER (2012)
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: A clinical review
J. Chirgwin et al.
BREAST (2011)
A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer
Barry Mirtsching et al.
CLINICAL BREAST CANCER (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Christopher Lobo et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer
Alison K. Conlin et al.
CLINICAL BREAST CANCER (2010)
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non Small-Cell Lung Cancer
Giorgio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)
V. Roy et al.
ANNALS OF ONCOLOGY (2009)
Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
William J. Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients
Neil Desai et al.
TRANSLATIONAL ONCOLOGY (2009)
Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status
Neil P. Desai et al.
ANTI-CANCER DRUGS (2008)
Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied
Daniela A. Brito et al.
JOURNAL OF CELL BIOLOGY (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes
Joanne L. Blum et al.
CLINICAL BREAST CANCER (2007)
Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer
John S. Link et al.
CLINICAL BREAST CANCER (2007)
Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy
I. Craig Henderson et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel
N Desai et al.
CLINICAL CANCER RESEARCH (2006)
Albumin-bound paclitaxel: a next-generation taxane
William J. Gradishar
EXPERT OPINION ON PHARMACOTHERAPY (2006)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
WJ Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer
NK Ibrahim et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)
A Sparreboom et al.
CLINICAL CANCER RESEARCH (2005)
Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes
G Watkins et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2005)
Extending survival with chemotherapy in metastatic breast cancer
J O'Shaughnessy
ONCOLOGIST (2005)
The spindle checkpoint, aneuploidy, and cancer
R Bharadwaj et al.
ONCOGENE (2004)
Pharmacological effects of formulation vehicles - Implications for cancer chemotherapy
AJ ten Tije et al.
CLINICAL PHARMACOKINETICS (2003)
Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: A phase I trial
H Safran et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
